Back to top
more

Cardinal Health (CAH)

(Delayed Data from NYSE)

$153.41 USD

153.41
3,229,121

-3.19 (-2.04%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $153.70 +0.29 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (69 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Why Cardinal Health (CAH) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Glaukos (GKOS) Q4 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Glaukos' (GKOS) fourth-quarter revenues beat estimates as well as gained year over year. Gross margin improve, while higher operating expenses lead to a wider operating loss.

Zacks Equity Research

Tandem Diabetes (TNDM) Posts Wider Q4 Loss, Gross Margin Down

by Zacks Equity Research

Tandem Diabetes (TNDM) reports a higher-than-expected loss in the fourth quarter of 2023.

Maharathi Basu headshot

5 Stocks Favored by Brokers Amid the Current Uncertainty

by Maharathi Basu

We believe that stocks like Deutsche Bank (DB), Cross Country Healthcare (CCRN), Bread Financial (BFH), American Axle (AXL) and Cardinal Health (CAH) should be on an investor's watchlist.

Zacks Equity Research

Here's Why You Should Retain Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on continued geographic expansion.

Zacks Equity Research

Boston Scientific (BSX) Surges 4.6%: Will the Rally Continue?

by Zacks Equity Research

Boston Scientific (BSX) is benefitting from an impressive gain in MedSurg market share and the strong adoption of WATCHMAN FLX.

Zacks Equity Research

Charles River (CRL) Gains From CRADL Amid Soft Market Scenario

by Zacks Equity Research

Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.

Zacks Equity Research

Sight Sciences (SGHT) to Expand in Europe With New Launch

by Zacks Equity Research

By tapping into the European market, Sight Sciences (SGHT) aims to capitalize on the growing demand for advanced eye care technologies.

Zacks Equity Research

Avanos (AVNS) Q4 Earnings Lag Estimates, Margins Contract

by Zacks Equity Research

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall fourth-quarter results reflect soft performances.

Zacks Equity Research

Here's Why You Should Buy Zimmer Biomet (ZBH) Stock Now

by Zacks Equity Research

Strategic plans to drive the Knee business bode well for Zimmer Biomet (ZBH).

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Surpass, Margins Down

by Zacks Equity Research

Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.

Zacks Equity Research

Medtronic (MDT) Q3 Earnings Beat Estimates, 2024 View Up

by Zacks Equity Research

Medtronic's (MDT) third-quarter organic growth reflects broad strength across businesses and geographies.

Zacks Equity Research

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) increased adoption of AirSense10 and AirSense11 devices.

Zacks Equity Research

GE HealthCare's (GEHC) Tie-Up to Improve Care Accessibility

by Zacks Equity Research

GE HealthCare's (GEHC) latest alliance is likely to include investment in new technology systems, digital tools and resources, service and support across a variety of care areas.

Zacks Equity Research

Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.

Zacks Equity Research

Illumina (ILMN) Rides on NGS Portfolio Expansion Amid Macro Woe

by Zacks Equity Research

In reproductive health, Illumina (ILMN) primarily focuses on driving noninvasive prenatal testing (NIPT) adoption globally.

Zacks Equity Research

SenesTech (SNES) Expands in the Netherlands With Q-chem Deal

by Zacks Equity Research

SenesTech's (SNES) collaboration with Q-chem strategically aligns with the Netherlands' Integrated Pest Control program.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors remain optimistic for Penumbra (PEN), backed by the strength of its portfolio.

Zacks Equity Research

Thermo Fisher (TMO) Introduces Dionex Inuvion IC system

by Zacks Equity Research

Thermo Fisher's (TMO) Dionex Inuvion system helps labs operate more effectively by providing simple, adjustable workflows and a small footprint.

Zacks Equity Research

Is Cardinal Health (CAH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

QIAGEN (QGEN) Earns Notable Recognitions in Sustainability

by Zacks Equity Research

QIAGEN (QGEN) achieves the ACT Label for new eco-friendly QIAwave products and the first My Green Lab Platinum certification.

Zacks Equity Research

National Vision (EYE) Hurt by Business Closure, Macro Woe

by Zacks Equity Research

National Vision's (EYE) impending termination of the long-term partnership with Walmart is likely to significantly impact its business.

Zacks Equity Research

Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VALQ

Zacks Equity Research

IDEXX (IDXX) Unveils Pet Owner Engagement Software Solution

by Zacks Equity Research

IDEXX's (IDXX) Vello software is an intuitive solution designed specifically for practice management software that enables practitioners to interact with pet owners before and after visits.